Goldman Sachs
BDTX icon

Goldman Sachs’s Black Diamond Therapeutics BDTX Stock Holding History

Goldman Sachs’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Sell
288,780
-395,638
-58% -$968K ﹤0.01% 5662
2026
Q1 		$1.46M Buy
684,418
+359,091
+110% +$854K ﹤0.01% 4806
2025
Q4 		$791K Sell
325,327
-123,691
-28% -$438K ﹤0.01% 5295
2025
Q3 		$1.7M Buy
449,018
+98,374
+28% +$288K ﹤0.01% 4616
2025
Q2 		$870K Sell
350,644
-128,743
-27% -$248K ﹤0.01% 4801
2025
Q1 		$743K Sell
479,387
-4,449
-0.9% -$9.33K ﹤0.01% 4921
2024
Q4 		$1.04M Buy
483,836
+202,820
+72% +$581K ﹤0.01% 4802
2024
Q3 		$1.22M Buy
281,016
+217,896
+345% +$1.19M ﹤0.01% 4503
2024
Q2 		$294K Sell
63,120
-270,128
-81% -$1.45M ﹤0.01% 5117
2024
Q1 		$1.69M Buy
333,248
+287,263
+625% +$1.16M ﹤0.01% 3983
2023
Q4 		$129K Buy
+45,985
New +$108K ﹤0.01% 5251
2023
Q2 		– Sell
-36,679
Closed -$69.3K – 5753
2023
Q1 		$69.3K Sell
36,679
-327
-0.9% -$751 ﹤0.01% 5507
2022
Q4 		$66.6K Sell
37,006
-17,972
-33% -$32.4K ﹤0.01% 5560
2022
Q3 		$93K Sell
54,978
-47,148
-46% -$145K ﹤0.01% 5704
2022
Q2 		$251K Sell
102,126
-78,971
-44% -$184K ﹤0.01% 5519
2022
Q1 		$502K Buy
181,097
+48,941
+37% +$179K ﹤0.01% 5315
2021
Q4 		$704K Buy
132,156
+6,050
+5% +$42.3K ﹤0.01% 5116
2021
Q3 		$1.07M Sell
126,106
-67,356
-35% -$665K ﹤0.01% 4692
2021
Q2 		$2.36M Buy
193,462
+108,934
+129% +$2.15M ﹤0.01% 4046
2021
Q1 		$2.05M Buy
84,528
+12,272
+17% +$331K ﹤0.01% 3959
2020
Q4 		$2.32M Buy
72,256
+64,384
+818% +$2.12M ﹤0.01% 3621
2020
Q3 		$238K Sell
7,872
-9,145
-54% -$278K ﹤0.01% 4847
2020
Q2 		$718K Sell
17,017
-73,020
-81% -$2.69M ﹤0.01% 4167
2020
Q1 		$2.25M Buy
+90,037
New +$2.74M ﹤0.01% 3219

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Goldman Sachs's BDTX Position: Q2 2026 in Review

Goldman Sachs reduced its Black Diamond Therapeutics (BDTX) stake by 58% in Q2 2026, selling an estimated $968K and leaving 288,780 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #5662.

Goldman Sachs first reported a position in BDTX in Q1 2020 and has held it in 24 quarters since. The position peaked at $2.36M in Q2 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Goldman Sachs held 288,780 shares of Black Diamond Therapeutics worth $534K as of Q2 2026.
  • Goldman Sachs sold 395,638 Black Diamond Therapeutics shares in Q2 2026, an estimated $968K.
  • Black Diamond Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5662 holding.
  • Goldman Sachs first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Black Diamond Therapeutics position peaked at $2.36M in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.